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Poster Session I 47CFU-IL3 activity, but lost the capacity to enhance CFU-E. Addi-
tionally, a requirement for IL-9R signaling (IL-9Ra/gc) in BMC
was supported by the absence of Treg CFU-E enhancement of gc
KO marrow. Finally, Treg augmentation of CFU-E in transwell
cultures using B6-wt and B6-Class II-/- Lin- populations showed
that this enhancing activity: a) was not contact dependent and b)
did not require MHC class II expression on the targeted popula-
tions. These findings reveal two distinct pathways of regulation,
i.e. inhibition and enhancement as defined by cytokines, contact de-
pendency and an MHC class II requirement. Current studies have
found neither perforin or fasL are required to mediate either of
these pathways. In total, these results demonstrate for the first
time that Tregs can modulate activity which is critically important
to successful engraftment in clinical BMT, in addition to adaptive
and innate immune responses.122
G-CSF AND FLT3 LIGAND PROMOTE RECOVERY OF HEMATOPOIESIS AF-
TER TOTAL BODY IRRADIATION (TBI) WITHOUT HEMATOPOIETIC STEM
CELL SUPPORT
Georges, G.E.1,2, Pillai, J.N.1, Lesnikov, V.1, Lesnikova, M.1,
Yang, Y.-J.1, Aragon, A.1, Mielcarek, M.1,2 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2University of Washington, Seattle, WA.
Hematopoietic cells are highly sensitive to radiation damage and
their loss after radiation exposure results in lethal infections. We
asked if intensive supportive care and hematopoietic-specific cyto-
kine treatment after doses of TBI that were previously identified
as lethal would permit survival and promote recovery of endoge-
nous hematopoiesis without requiring hematopoietic stem cell sup-
port in the well-established dog model. Historical results showed
that after 4 Gy TBI and standard supportive care, only 1 of 28
dogs survived with recovery of endogenous hematopoiesis. The
new intensive supportive care regimen for dogs after irradiation in-
cluded an antibiotic use algorithm for empiric treatment of pro-
longed neutropenia and fever and blood transfusion and
intravenous fluid support. Intensive supportive care given to 60
dogs after TBI resulted in significantly improved survival compared
to the historical supportive care.With intensive supportive care, we
observed high rates of survival in dogs following exposure of up to 7
Gy TBI with complete endogenous hematopoietic recovery. Cyto-
kine treatment consisting of granulocyte colony stimulating factor
(G-CSF) alone or combined G-CSF and fms-like tyrosine kinase
3 (flt-3) ligand, (FL) given after TBI did not significantly improve
long term survival compared to recipients of intensive supportive
care alone, but it significantly decreased the duration of intensive,
expensive supportive care. For all cohorts receiving cytokines after
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Survival at . day 1120.ive care alone (p\ 0.002). Treatment with the combination of G-
CSF (10 mg/kg/day) and FL (100 mg/kg/day), starting 2 hours after
TBI and continuing until recovery of ANC . 1000/mL resulted in
significantly more rapid recovery of ANC and platelets compared to
G-CSF alone. Follow-up of all surviving dogs .6 months after ir-
radiation showed sustained hematopoiesis and immune reconstitu-
tion. These studies show that in this model, hematopoietic stem
cells survive doses of TBI up to 7 and 8 Gy without requiring infu-
sion of either autologous or allogeneic hematopoietic stem cells,
that intensive supportive care is sufficient to permit reliable survival
after 7 Gy TBI, and that the cytokine combination of G-CSF and
FL is more effective than G-CSF in promoting rapid recovery of
neutrophils and platelets after moderately high dose TBI. The re-
sults are relevant for the treatment of victims of terrorist or acciden-
tal radiation exposure.123
INCREASED EXPANSION, HOMING AND ENGRAFTMENT OF CYTOKINE-
CULTURED CORD BLOOD-DERIVED CD341 CELLS BY TREATMENT
WITH NICOTINAMIDE, A FORM OF VITAMIN B3
Peled, T.1, Adi, S.1, Rosenheimer, N.G.1, Shoham, H.1, Daniely, Y.1,
Nagler, A.2, Rechavi, G.3, Amariglio, N.3, Hirsch, J.J.3, Fibach, E.4,
Peled, A.5 1Gamida Cell Ltd., Jerusalem, Israel; 2Chaim Sheba Medical
Center, Tel-Hashomer, Israel; 3Chaim Sheba Medical Center Tel
Hashomer 52621& Sackler School of Medicine Tel Aviv University,
Tel Aviv, Israel; 4Hadassah - Hebrew University Medical Center, Jeru-
salem, Israel; 5Hadassah - Hebrew University Medical Center, Jerusa-
lem, Israel.
Strategies to expandCD341 cells in vitro and to enhance their re-
populating activity in vivo may improve the clinical outcome of
transplantation. Alas, low engraftment efficacy after ex vivo expan-
sion limits the clinical utility of cultured CD341 cells.
Our study demonstrates that nicotinamide (NAM), a form of vi-
tamin B3 and an inhibitor of ADP ribosylation, attenuates the en-
graftment deficiency of cultured CD341 cells.
Treatment with NAM of cytokine-cultured cord blood (CB) de-
rived CD341 cells significantly increased the proportion of early
(CD38- CD341Lin-) HPC subsets within the expanded CD341
cell population.NAM-treated cultures had 7.5-foldmore SCIDRe-
populating Cells (SRC) than cytokine-alone treated cultures and 9
fold more SRC over the seeded number of SRC. Moreover, an en-
graftment advantage of NAM cultured cells was observed as early as
12 days after transplantation.
A mechanistic probe of NAM cultured cells demonstrated an ini-
tial slower proliferation rate of CD341 cells treated with NAM
than cells exposed to cytokines alone. Treatment with NAM en-
hances CD341 cells migration in response to CXCL12, the ligand
for CXCR4. Furthermore, NAM treatment stimulates significantly
the homing efficacy of cultured CD341 cells to the bone marrow of
NOD/SCID mice. This may explain, at least in part, the increased
engraftment efficacy of cells cultured with cytokines 1 NAM. Ge-
nome wide expression profiles of CD341 cells re-isolated from cy-
tokines and cytokines1NAM cultures demonstrate transcriptional
modulation byNAMof genes implicated in cell migration, motility,
adhesion, protein localization and cell cycle.
Our study unveils a novel activity ofNAMand suggests its clinical
utility in cord blood transplantation.124
MESENCHYMAL STEM CELLS SUPPORT EX VIVO UMBILICAL CORD
BLOOD EXPANSION BY A CONTACT-DEPENDENT ANTI-APOPTOTIC EF-
FECT
Chu, P.1, Huang, J.1, Prasath, A.2, Hwang, W.1 1SingHealth and
Duke-NUS Graduate Medical School, Singapore, Singapore; 2Singapore
General Hospital, Singapore, Singapore.
Aims: Ex vivo expansion of stem and progenitor cells in umbilical
cord blood (UCB) is enhanced by co-culture with mesenchymal
stem cells (MSC). We investigated the mechanism of this
48 Poster Session Ienhancement to determine the role of contact, the effect on prolif-
eration and apoptosis, as well as possible molecular mechanisms.
Methods: CD34-selected or non-selected UCB cells were co-cul-
tured with MSC under serum-free conditions. CD451 and
CD341 cells were detected b flow-cytometry. Progenitor function
was determined by colony forming unit assay. Non-viable and early
apoptotic cell detection was based on 7-Amino-ActinomycinD/An-
nexin-V staining. Cell cycle analysis was based on propidium iodide
staining. Results: CD341 selected as well as non-selected UCB
cells had 2 to 5 fold enhancement of growth when cultured on
MSCs compared to expansion in cytokines alone. Over 90% of
the proliferative activities were contributed by the CD34-selected
cells. Progenitor cells expanded rapidly only during the first 7
days of co-culture but declined afterwards. The enhancement on
UCB expansion was maximized when the MSC layer was in direct
contact with the UCB cells. UCB cells co-cultured with MSC re-
sulted in 2- to 4-fold lower apoptotic cell fraction, andUCB cell-cy-
cling activities were not affected. Conclusions: The main
mecahnism of enhancement of CBU cultures on MSC co-cultures
appears to be due to rescue of cells from apoptosis during the initial
few days of culture rather than due to a direct effect on augmenting
proliferation. The molecules involved in this interaction aree being
investigated in our laboratory.125
STROMA FORMATION FROM FRESH AND CRYOPRESERVED MONONU-
CLEAR CELLS OBTAINED AT THE PRE AND POST-MOBILIZATION
PHASES FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION
Schimiegue, D.M.2, Silva, L.1, Dreyfuss, J.L.3, Zattar, K.C.2,
Nader, H.B.3, Borelli, P.4, Oliveira, J.S.R.2 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2University Federal of
Sao Paulo, Sao Paulo, Brazil; 3University Federal of Sao Paulo, Sao
Paulo, Brazil; 4University State of Sao Paulo, Sao Paulo, Brazil.
Background: Autologous hematopoeitic stem cell transplanta-
tion (auto-HSCT) comprises the manipulation of bone marrow
and peripheral blood HSC by cryopreservation and posterior thaw-
ing. These manipulations can cause cell damage, especially in pa-
tients submitted to aggressive induction remission chemotherapy,
radiation and auto-HSCT conditioning. Study Design and
Methods: Thirty-two bone marrow samples (22 patients and 10
controls) were collected at pre-mobilization phase and 27 (20 pa-
tients and 7 controls) at post-mobilization, respectively. Fresh or
cryopreserved mononuclear cells were cultured for eleven months
and had their confluency capacity analyzed. Results: In regard to
confluency achievement, there was no difference between fresh
and cryopreserved samples from pre-mobilization phase. Apart
from this, cells from 6 of the 11 (54%) fresh samples collected
from patients at pre-mobilization phase achieved $70% conflu-
ency. Cells from all (5 of 5, 100%) fresh control samples collected
at this phase and from 4 of the 5 (80%) cryopreserved, achieved
$70% confluency. Cells from 5 of the 10 (50%) fresh samples col-
lected from patients during the post-mobilization and 4 of the 10
(40%) cryopreserved samples reached$70% confluency. Consider-
ing the control group from this phase, cells from half (1 of 2) of the
fresh samples and from 1 of the 5 cryopreserved samples, achieved
$70% confluency. Conclusion: Stroma establishment from nor-
mal hematopoietic progenitors post mobilization is reduced when
compared to samples obtained from patients with hematologic ma-
lignancies, most probably due to higher sensitivity of healthy pro-
genitor cells to cryopreservation and thawing-induced damage.126
CO-TRANSPLANTATION OF MESENCHYMAL STEM CELLS AND HEMATO-
POIETIC STEM CELLS IN ß-THALASSEMIA PATIENTS
Ghavamzadeh, A., Valizadeh, N., Alimoghaddam, K., Karimi, A.,
Bahoush, G., Bashtar, M., Shamshiri, A.R., Jalili, M., Mosavi, A.S.,
Shahriari, Z., Basirpanah, S., Khalilvand, S., Chardouli, B.,Khatami, F. University of Tehran/Medical Sciences, Tehran, Islamic Re-
public of Iran.
Background: mesenchymal stromal cells are immunomodoula-
trory and may have important role in engraftement and GVHD/
HVGD. we studied co-transplantation of ex vivo expanded MSCs
andHSC.Patients andMethods: In this study, we coadministered
culture-expanded MSCs with HLA-identical sibling-matched
HSCs in b-thalassemia patients. Between Nowember 2006 and
February 2007, 10 ß-thalassemia patients were enrolled. Patients re-
ceived Cyclophosphamide-based or Fludarabine –based condition-
ing regimens and short course methotrexate and cyclosporine as
GVHD prophylaxis. On day 0, patients were given MSCs intrave-
nously (1.0–2.24  106/kg) 4 hours before infusion of either bone
marrow or peripheral blood stem cells. Outcomes of transplantation
compared between these patients with 50 matched - historical con-
trols group which were transplanted with HSCs in last years.
Matching criteria were included: recipients’ gender, source of
stem cell (bone marrow or peripheral blood), thalassemia group (in-
termediate or major), class of ß-thalassemia major (I, II, III) . Re-
sults: Chills and fever was only notable toxicity in MSC group.
The median time to achieve WBC engraftment $0.5  109/L
was 12.5 days (range 10–20 days) forMSC group and 12 days (range
6–52 days) in matched-historical control group (p-value 5 0.67).
Themedian time to achieve platelet engraftment$20 109/Lwas
18 days (range 12–30 days) forMSC group and 22 days (range 10–81
days) for comparison group (p-value 5 0.02). Incidence of acute
GVHDwas 80% and 76% inMSC and historical-matched group re-
spectively (p-value 5 1). 3-month overall survival rate was 90% and
91.7% in MSC and matched control group respectively (p-value 5
0.29). 100-day disease free survival rate was 80% and 87.8% in
MSC group and matched historical control group respectively (p-
value 5 0.27). Conclusion: In this study we demonstrated that co-
transplantation of HLA-identical sibling MSCs with HSCs is seems
to be safe. we can’t find statistical significant difference in acute
GVHD incidence, severity, OS, DFS, Median time to WBC recov-
ery between MSC group and compartion group.most probably ex-
plantation is small number of patients in study group.median time
to plt recovery was shorter in MSC group (p-value 5 0.02).
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MESENCHYMAL STEM CELLS EXERT DIFFERENTIAL EFFECTS ON ALLO-
ANTIGEN- AND VIRUS-SPECIFIC T CELLS
Karlsson, H.1,2, Samarasinghe, S.1, Ball, L.3, Sundberg, B.2,
Lankester, A.C.3, Dazzi, F.4, Rao, K.5, Veys, P.5, Le Blanc, K.2,
Ringden, O.2, Amrolia, P.J.1,5 1 Institute of Child Health, London,
United Kingdom; 2Karolinska Institute and Karolinska University Hos-
pital Huddinge, Stockholm, Sweden; 3Leiden University Medical Centre,
Leiden, Netherlands; 4 Imperial College School of Medicine, London,
United Kingdom; 5Great Ormond Street Hospital for Children, London,
United Kingdom.
Objectives: Mesenchymal stem cells (MSC) suppress alloanti-
gen-induced proliferation, interferon-g (IFN-g) production and
cytolytic killing in vitro and infusion of third-party MSC appears
a promising therapy for acute GVHD. However, little is known
about the specificity of immunosuppression by MSC and in partic-
ular the effect on cell-mediated immunity to infectious pathogens.
We have studied the effect of MSC on virus-specific T-cell re-
sponses. Results: Peripheral blood mononuclear cells (PBMC)
from 6 normal donors were stimulated for with autologous lympho-
blastoid cell lines (LCL) (EBV), pp65 peptides (CMV), an adenovi-
ral vector Ad5f35 (Ad) or allogeneic PBMC (Allo), in the presence
or absence of third-party MSC (MSC/PBMC ratio 1:10). MSC sig-
nificantly suppressed proliferation in response to Allo (mean 61%
suppression, p 5 0.003), but had less effect on the response to
EBV (mean 42% suppression, p 5 0.016) and no suppression of
the response to CMV or Ad. MSC had no effect on expansion of
EBV and CMV pentamer-specific T-cells after stimulation with
their cognate antigen. ELISPOT assays demonstrated that MSC
significantly inhibited IFN-g production in response to Allo
(mean SFC/105 cells 1125 6 274 without MSC, 263 6 49 with
MSC) and to a smaller extent to EBV (3181 6 548 vs 2147 6
387), but not to CMV (2535 6 374 vs 2532 6 311). Established
EBV-specific cytotoxic T-cells (EBV-CTL) from 5 donors were
